MA30660B1 - Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol. - Google Patents

Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.

Info

Publication number
MA30660B1
MA30660B1 MA31660A MA31660A MA30660B1 MA 30660 B1 MA30660 B1 MA 30660B1 MA 31660 A MA31660 A MA 31660A MA 31660 A MA31660 A MA 31660A MA 30660 B1 MA30660 B1 MA 30660B1
Authority
MA
Morocco
Prior art keywords
pro
igf
variant
pegylated
polyethylene glycol
Prior art date
Application number
MA31660A
Other languages
English (en)
Inventor
Stephan Fischer
Friederike Hesse
Hendrik Knoetgen
Kurt Lang
Friedrich Metzger
Joerg Thomas Regula
Christian Schantz
Andreas Schaubmar
Hans Joachim Schoenfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37667695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30660(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30660B1 publication Critical patent/MA30660B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédé de production de conjugués du facteur de croissance analogue à l'insuline 1 et de polyéthylèneglycol Procédé de production d'un IGF-I ou d'une variante d'IGF-1 pégylé(e) sur la lysine, ladite variante comprenant un ou deux aminoacides choisis dans le groupe constitué par la lysine 27, 65 et/ou 68 remplacés indépendamment par un autre aminoacide polaire, caractérisé en ce que l'on cultive une cellule hôte procaryote comprenant un vecteur d'expression contenant un acide nucléique codant pour une protéine de fusion comprenant ledit IGF-I ou ladite variante d'IGF-I lié(e) en position N-terminale à l'extrémité C-terminale d'un propeptide, ledit propeptide se terminant à l'extrémité C-terminale par les aminoacides -Y-Pro, où Y est choisi dans le groupe constitué par Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro ou Pro-Arg-Pro, on récupère ladite protéine de fusion et on la soumet à une pégylation, on coupe ladite protéine de fusion pégylée avec une IgA-protéase, et on récupère ledit IGF-I ou ladite variante d'IGF-I pégylé(e). L'IGF-I ou la variante d'IGF-I pégylé(e) est utile pour le traitement de troubles neurodégénératifs comme la maladie d'Alzheimer.
MA31660A 2006-08-31 2009-02-25 Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol. MA30660B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06018170 2006-08-31

Publications (1)

Publication Number Publication Date
MA30660B1 true MA30660B1 (fr) 2009-08-03

Family

ID=37667695

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31660A MA30660B1 (fr) 2006-08-31 2009-02-25 Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.

Country Status (21)

Country Link
US (4) US7625996B2 (fr)
EP (1) EP2059261B1 (fr)
JP (1) JP5184532B2 (fr)
KR (1) KR101106931B1 (fr)
CN (1) CN101511390B (fr)
AR (1) AR062575A1 (fr)
AU (1) AU2007291502B2 (fr)
BR (1) BRPI0715943A2 (fr)
CA (1) CA2662062C (fr)
CL (1) CL2007002502A1 (fr)
CO (1) CO6251278A2 (fr)
CR (1) CR10591A (fr)
ES (1) ES2397660T3 (fr)
IL (1) IL196736A (fr)
MA (1) MA30660B1 (fr)
MX (1) MX2009002011A (fr)
NO (1) NO20090451L (fr)
PE (1) PE20080912A1 (fr)
RU (1) RU2009106118A (fr)
TW (1) TW200819468A (fr)
WO (1) WO2008025528A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674113A1 (fr) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
CA2822302A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Procedes pour alterer la differenciation osteoclaste
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
EP2249853A4 (fr) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d' esters
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
EP2376099A4 (fr) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp Facteurs de croissance semblables à l'insuline à base d'yl exprimant une haute activité au récepteur de l'insuline
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CA2786340C (fr) * 2010-02-11 2017-08-22 F. Hoffmann-La Roche Ag Conjugues de l'igf-i et du poly(ethylene glycol)
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585102B1 (fr) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
HK1210192A1 (en) 2012-07-19 2016-04-15 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
EP3395358B1 (fr) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Dimères d'un analogue d'insuline
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
WO2014205617A1 (fr) * 2013-06-24 2014-12-31 Shandong University Peptide marqué au lanthanide et utilisation de celui-ci
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法
CN113329762A (zh) * 2018-12-19 2021-08-31 美国联合生物医学公司 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位
EP3911668A1 (fr) 2019-01-18 2021-11-24 The Regents of the University of Colorado, a body corporate Peptides antimicrobiens alpha-hélicoïdaux amphipathiques pour le traitement d'infections par des agents pathogènes à gram-négatif

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) * 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5861373A (en) 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (fr) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 utilise pour ameliorer l'etat pathologique du systeme nerveux
EP0679095A1 (fr) 1992-11-25 1995-11-02 Amgen Boulder Inc. Facteur de croissance insulinoide modifie
WO1995032003A1 (fr) 1994-05-24 1995-11-30 Amgen Boulder Inc. Facteurs de croissance proches de l'insuline modifies
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US7067485B2 (en) 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
WO1999055362A1 (fr) 1998-04-29 1999-11-04 Genentech, Inc. Formulations de igf-i sechees par pulverisation
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
EP0972838B1 (fr) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Système de sélection par complémentation d' une auxotrophie en absence d'antibiotique chez E. coli
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU763039B2 (en) 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
ATE389416T1 (de) * 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
CA2410974A1 (fr) * 2000-05-16 2002-11-15 Dnavec Research Inc. Polypeptides de clivage de repetitions telomeriques
EP1286700A2 (fr) 2000-06-01 2003-03-05 Universite Catholique De Louvain Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20020082215A1 (en) 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002259281A1 (en) 2001-05-21 2002-12-03 Nektar Therapeutics Al, Corporation Antibodies specific for poly(ethylene glycol)
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
EP1674113A1 (fr) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugués de l'IGF-1 et du poly(éthylène glycol)
JP4988599B2 (ja) 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP5173018B2 (ja) 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用

Also Published As

Publication number Publication date
CN101511390A (zh) 2009-08-19
KR101106931B1 (ko) 2012-01-25
AU2007291502B2 (en) 2012-05-31
US20080119409A1 (en) 2008-05-22
IL196736A (en) 2013-10-31
MX2009002011A (es) 2009-03-05
US8476232B2 (en) 2013-07-02
US7625996B2 (en) 2009-12-01
CR10591A (es) 2009-04-03
PE20080912A1 (es) 2008-07-19
AR062575A1 (es) 2008-11-19
US20130065831A1 (en) 2013-03-14
WO2008025528A1 (fr) 2008-03-06
EP2059261A1 (fr) 2009-05-20
CO6251278A2 (es) 2011-02-21
CA2662062A1 (fr) 2008-03-06
IL196736A0 (en) 2009-11-18
CA2662062C (fr) 2015-06-23
TW200819468A (en) 2008-05-01
US20100035817A1 (en) 2010-02-11
BRPI0715943A2 (pt) 2013-07-30
US20100210547A1 (en) 2010-08-19
JP5184532B2 (ja) 2013-04-17
RU2009106118A (ru) 2010-10-10
KR20090046875A (ko) 2009-05-11
ES2397660T3 (es) 2013-03-08
NO20090451L (no) 2009-02-26
CN101511390B (zh) 2013-04-24
EP2059261B1 (fr) 2012-10-24
JP2010501192A (ja) 2010-01-21
AU2007291502A1 (en) 2008-03-06
CL2007002502A1 (es) 2008-05-30

Similar Documents

Publication Publication Date Title
MA30660B1 (fr) Procedes de production de conjugues du facteurs de croissance i de type insuline (igf-i) et de polyethyleneglycol.
WO2008025527A8 (fr) Procédé de production du facteur de croissance 1 analogue à l'insuline
Malik Protein fusion tags for efficient expression and purification of recombinant proteins in the periplasmic space of E. coli
HRP20150326T1 (hr) Stabilizirani polipeptidi faktora rasta nalik na inzulin
RU2018119141A (ru) Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция
CN111757891B (zh) 索马鲁肽、利拉鲁肽和glp-1的化学-酶法合成
WO2002090495A8 (fr) Systeme d'expression de proteine sumo a scission rapide pour proteines difficiles a exprimer
ATE421977T1 (de) Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
WO1999038984A1 (fr) Procede de production de peptide au moyen d'un peptide accessoire
JP7246323B2 (ja) Ｓ２又はｓ２’ポケット中の突然変異を有するサブチリシンバリアント
US10000544B2 (en) Process for production of insulin and insulin analogues
KR100989413B1 (ko) 새로운 융합파트너를 이용한 재조합 단백질의 제조방법
US20150315259A1 (en) Method of producing a recombinant peptide
WO2019143193A9 (fr) Homologue de fusion n-terminal pour la production d'un polypeptide recombinant, et procédé de production d'un polypeptide recombinant utilisant ce dernier
JP2026507112A (ja) ペプチドの産生及び精製のための方法及び組成物
CA2327524A1 (fr) Procede de controle de clivage par la protease de l'ompt
Wong et al. Escherichia coli: A versatile platform for recombinant protein expression
WO2017222369A1 (fr) Couplage enzymatique de (oligo)peptides à la chaîne b d'un ligand du récepteur de l'insuline
JP5743370B2 (ja) 改善されたフォールディングの空気ガス処理によってインスリンを抽出する方法
KR100980457B1 (ko) 대장균에서 활성형 인간 인터루킨-6의 생산 및 정제방법
RU2006114756A (ru) Способ расщепления полипептидов с использованием варианта протеазы омрт
CA3060389C (fr) Variantes de subtilisine ayant une mutation dans la poche s2 ou s2'
HK40015407A (en) Subtilisin variants having a mutation in the s2 or s2' pocket
WO2007056524A3 (fr) Chimeres st3gal-1/st6galnac-1